Search
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … [A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated.[A263211]
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingProducts: CISTICID ® 600MGCalcium gluconate
go.drugbank.com/drugs/DB11126ApprovedInvestigationalVet approvedSupplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. … Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate.
Mixtures: CAL-EMIL, ELETTROLITICA DI REINTEGRAZIONE CON GLUCOSIO E SODIO GLUCONATO FKISynonyms: D-gluconic acid, calcium salt (2:1), Calcium di-gluconateZeatin
go.drugbank.com/drugs/DB11337InvestigationalAn aminopurine factor in plant extracts that induces cell division. (Grant & Hackh's Chemical Dict, 5th ed)
Categories: Heterocyclic Compounds, 2-RingSynonyms: (E)-2-methyl-4-(1H-purin-6-ylamino)but-2-en-1-ol, N6-(4-Hydroxyisopentenyl)adenineInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalBy binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol. … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, Compounds used in a research, industrial, or household settingProducts: LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML, Sybrava 284mg/1.5ml Solution for Injection in Pre-filled SyringemRNA-1010
go.drugbank.com/drugs/DB22484Approved[L64058] Unlike conventional egg- or cell-based inactivated influenza vaccines, mFLUSIVA is built on the mRNA platform and is manufactured without an egg- or cell-based process. … [L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Categories: CCR5 Co-receptor Antagonist, Cytochrome P-450 SubstratesProducts: CELSENTRI® 150 MG, CELSENTRI® 300 MGCap-specific mRNA (nucleoside-2'-O-)-methyltransferase
go.drugbank.com/bio_entities/BE0001402TargetVACVAt the mRNAs 5' end, methylates the ribose 2' OH group of the first transcribed nucleotide, thereby producing a 2'-O-methylpurine cap.
Polypeptides: Cap-specific mRNA (nucleoside-2'-O-)-methyltransferasePegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000,A235005] Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to both forms of hemolysis that threaten patients with PNH. … [A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization.
Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLESirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: LIKMUN-E, P-HYSPLANTetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate Drug Metabolism
smpdb.ca/view/SMP0130603MetabolicTetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate passes through the liver and is then excreted from the body mainly through the kidney. … Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis.